Article

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages

2024-08-13

Abstract excerpt

Protection from COVID-19 vaccination is suboptimal in many immunocompromised individuals. In March 2024, the Food and Drug Administration issued an Emergency Use Authorization for pemivibart (Permagard/VYD222), an engineered human monoclonal antibody, for pre-exposure prophylaxis in this vulnerable population. However, SARS-CoV-2 has since evolved extensively, resulting in multiple Omicron JN.1 sublineages. We the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 39730744-cab0-5c29-b2b2-9dba490bd60f
DOI: 10.1101/2024.08.12.607496

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineagesDOI 10.1101/2024.08.12.607496Read

Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodiesSemantic proximity Read

VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individualsSemantic proximity Read

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usageSemantic proximity Read

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.Semantic proximity Read

Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasionSemantic proximity Read

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.Semantic proximity Read

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodiesSemantic proximity Read

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2Semantic proximity Read

Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineageSemantic proximity Read

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineagesSemantic proximity Read

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsSemantic proximity Read

Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusionSemantic proximity Read